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Numerous systemic diseases share immunopathogenic mechanisms. This article reviews the
proposed etiologies and immunopathogenic mechanisms of a group of diseases which share
pulmonary and renal abnormalities. Specifically, we discuss the following diseases: Good-
pasture's syndrome, systemic lupus erythematosus, progressive systemic sclerosis, Wegener's
granulomatosis, lymphomatoid granulomatosis, and Churg-Strauss syndrome.
INTRODUCTION
This article reviews the proposed etiologies and immunopathogenic mechanisms
ofa group ofsystemic diseases which sharepulmonary and renal abnormalities. Em-
phasis will be placed on the immunopathogenesis of (1) Goodpasture's syndrome;
(2) two connective tissue (collagen vascular) diseases, systemic lupus erythematosus
and progressive systemic sclerosis (scleroderma); and (3) three granulomatous
vasculidities, Wegener's granulomatosis, lymphomatoid granulomatosis, and Churg-
Strauss syndrome. The clinical and chest radiographic manifestations of these
diseases have been reviewed recently in this journal [1]. It is our purpose here pri-
marily to review the immunologic mechanisms currentlv thought to be operating in
these diseases.
GOODPASTURE'S SYNDROME
Goodpasture's syndrome is charatcterized by pulmonary hemorrhage often with
hemoptysis, diffuse alveolar filling on the chest radiograph, anemia, and
glomerulonephritis [1-14]. It isgenerally felt that the pathologic changes observed in
this disease are an example of a cytotoxic antibody-nmediated (type II) reaction
(Table 1) because the disease appears to be due to an autoantibody which cross-
reacts with both glomerular and alveolar basement membranes [1,4,7,15]. In order
to understand the immunopathologic mechanisms which operate in this disease a
few general comments about autoimmune anti-glomerular basement membrane
disease are appropriate.
Immunologic tolerance refers to the inability of an individual to mount either a
cell-mediated or humoral immune response to a molecule or antigen to which it
would otherwise respond [16]. Normally, our own tissue antigens are protected from
immunologic attack by this tolerance. Our immune system has been programmed
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during fetal life to recognize our own antigens as self, thereby circumventing im-
munologically mediated destruction. Occasionally this tolerance falters, leading to
autoimmune diseases which appear to be mediated primarily by immunologic
responses directed against our own tissues. An ever-increasing number of diseases
are being found to be autoimmune in character. Of the renal diseases in this
category, Goodpasture's syndrome is an example.
Immunologically induced glomerulonephritis can be precipitated by either of two
major antibody-associated mechanisms which are divided on the basis of the
physical state of the involved antigen: tissue-fixed or soluble [17]. For the purposes
of this discussion we will be concerned only with anti-glomerular basement mem-
brane (anti-GBM) disease which is the prototype ofanti-tissue fixed antigen disease.
Several recent and excellent reviews of this subject exist and are recommended
highly [15,17,18].
Studies in Animals
In the 1930s, Masugi developed an animal model of nephrotoxic serum nephritis
[16]. Since that time several important observations of particular relevance to anti-
GBM disease have been made. In 1962, Steblay [19] immunized sheep with either
heterologous or homologous GBM in complete Freund's adjuvant. These animals
developed severe and progressive glomerulonephritis. Monkeys similarly immunized
likewise developed this disease. When the glomeruli ofthese animals wereexamined,
IgG and complement were observed in a linear pattern along the glomerular base-
ment membrane [20]. This suggested that glomerular lesions might result from the
formation of antibody directed against host glomerular basement membrane.
Lerner and Dixon verified the autoimmune character of these glomerular lesions by
transferring this disease to normal sheep using immunoglobulin from the serum of
the afflicted sheep [21].
It is now appreciated that experimentally induced anti-GBM glomerulonephritis
can assume either of two forms [17]. To produce the first type, anti-GBM antibody
is harvested from animals immunized with GBM and injected into normal animals.
When large amounts of antibody are injected, the animal develops an acute
glomerulonephritis due to fixing of anti-GBM antibody to glomerular basement
membrane. If only small amounts of anti-GBM antibody are injected, fixation of
antibody to glomerular basement membrane occurs but does so in amounts insuffi-
cient to elicit glomerulonephritis. Glomerulonephritis will eventually develop when
the animal produces antibody directed against anti-GBM antibody.
The second type of experimentally induced anti-GBM glomerulonephritis occurs
in some animals immunized with glomerular basement membrane in adjuvant [17].
In this case the anti-GBM antibody which develops cross-reacts with the animals'
own glomerular basement membrane and produces glomerulonephritis.
The renal injury in these two forms of experimentally induced anti-GBM
glomerulonephritis appears to be tied closely to the ability ofthese antibodies to fix
complement [17]. Activation of the complement systems results in neutrophil
chemotaxis to theglomeruli where lysosomal enzymes are released and participate in
renal injury. The crucial role ofthis cell was demonstrated whenit was observed that
neutrophil-depleted animals suffered less glomerular injury [17,22,23]. Recently,
research has shown that the macrophage also may play a pivotal role in some forms
ofglomerulonephritis. In this study, macrophages were shown to be present in large
numbers within the glomeruli of rabbits with experimentally induced glomerulone-
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phritis. Depletion of circulating macrophages prevented the accumulation of these
cells in glomeruli and largely prevented the development of glomerulonephritis [24].
The fact that not all anti-GBM glomerulonephritis is associated with observable
deposits of complement suggests that complement may not be necessary in all forms
of this disease [17].
Studies in Humans
The availability of this animal model has aided our ability to understand many of
the observations made in humans with Goodpasture's syndrome. This disease ap-
pears to be due to an autoantibody which cross-reacts with both glomerular and
alveolar basement membranes. Several pieces of evidence, in addition to the animal
data mentioned previously, support this view. First, linear deposits of im-
munoglobulin are found along the glomerular [25] (Fig. 1) and alveolar basement
membranes [26,27] (Fig. 2) in many of these patients. Most often the im-
munoglobulin is of the IgG class, although recently a patient with the clinical
manifestations ofGoodpasture's syndrome was found to have IgA deposits on both
alveolar and glomerular basement membranes [28]. Second, circulating anti-
glomerular basement membrane antibodies are found in the sera of most patients
with Goodpasture's syndrome [29]. Third, immunoglobulin eluted from the lung
tissue of a patient with Goodpasture's syndrome was shown to cross-react with
glomerular basement membrane [30]. Fourth, plasmaphoresis has been shown both
to lower the circulating levels ofanti-GBM antibodies and concomitantly to result in
clinical improvement [31,32]. Plasmaphoresis removes circulating anti-glomerular
basement membrane antibodies before they are able to bind in the kidney. The addi-
tion of cyclophosphamide therapy, which may decrease antibody production, also
may have a beneficial effect [32]. Fifth, the disease has recurred in a renal allograft
in a form similar to that present in the patient's own kidneys [33].
Theories ofPathogenesis
What triggers the onset of anti-GBM antibody formation remains an enigma.
Two theories regarding possible pathogenic mechanisms share widespread interest at
this time. The first theory suggests that antigenic determinants on glomerular base-
ment membrane tissue stimulate cytotoxic antibody formation. Glomerular base-
FIG. 1. Goodpasture's
syndrome-renal tissue
(post-mortem) revealing the
classic linear immuno-
fluorescent staining for IgG
anti-glomerular basement
membrane antibody. (Photo-
graph courtesy of Dr. M.
Kashkarian, Dept. of Pa-
thology, Yale University
School of Medicine.)
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FIG. 2. Goodpasture's
syndrome-lung tissue
(post-mortem) demonstrat-
ing positive immunoflu-
orescence for linear de-
posits of IgG antibody on
alveolar basement mem-
brane. (Photograph cour-
AS ^ ~-
tesy of Dr. M. Kashkarian, Dept. of Pathology, Yale
University School of Med-
icine.)
ment membrane antigenic material has been found in the urine of normal humans
[34] and animals [35,36]. When reinjected into the animal, immune disease results
[36]. These data suggest that glomerular basement membrane normally is capable of
stimulating an immune response but does not, possibly because it is anatomically se-
questered from contact with circulating immune cells and because it is eliminated in
the urine where it avoids contact with the systemic immune system. These same
authors have suggested that the initiating event in Goodpasture's may be an abnor-
mality which permits the reabsorption of this antigenic material. In this regard the
association of viral infection [37-39] and hydrocarbon inhalation [40,41] with
Goodpasture's syndrome is intriguing. Infection or exposure to hydrocarbons might
cause basement membrane antigens that are anatomically sequestered but poten-
tially immunogenic to be exposed to the immune system [6,7].
The second theory suggests that infectious agents may share antigenic deter-
minants with basement membrane. In this case infection with these organisms would
elicit the production ofantibody which would cross-react with basement membrane.
Wilson et al. [37] have suggested influenza A2 virus antigen might operate by this
mechanism. Additionally, experimental evidence suggests that streptococci possess
shared antigenic determinants [42]. However, there is currently little substantial
evidence to support this mechanism in human disease [33].
There is little doubt that anti-GBM antibodies participate in the renal manifesta-
tions of this disorder. However, while the evidence is highly suggestive, proof is
lacking that cross-reactivity of these antibodies with alveolar basement membrane
causes the pulmonary component of this syndrome. It is somewhat distressing that
circulating antibodies against alveolar basement membrane have not been described
[33]. Moreover, no model of pulmonary disease due to damage by anti-GBM an-
tibody exists [33]. Therefore, the possibility that cross-reactivity between anti-GBM
antibody and alveolar basement membrane is the mechanism for lung disease re-
mains only an assumption, albeit a reasonable one.
While the data stressing an association between hydrocarbon inhalation and
Goodpasture's is convincing, the low incidence of this disorder despite the large
numbers of people exposed to hydrocarbons is puzzling. It is possible that exposure
to fumes or infection may elicit disease only in genetically susceptible persons. The
occurrence of Goodpasture's syndrome in twins [43] and the recently observed
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association between HLA-DRW2 and Goodpasture's syndrome [44] strongly argue
for the importance of hereditary factors in this disease.
In summary, data obtained from animal studies and observations made on
humans with Goodpasture's syndrome argue convincingly for a central pathogenic
role for an anti-GBM antibody which cross-reacts with alveolar basement mem-
brane. Polymorphonuclear leukocytes, macrophages, and complement appear also
to be important in the development of alveolar and glomerular lesions. However,
the etiology and precise mechanisms of injury remain unknown.
SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic lupus erythematosus (SLE) is a multisystem disease associated with
autoimmune antibodies and circulating immune complexes. It is considered by some
to be a prototype of immune complex (type III) disease (Table 1) [45-47]. Renal in-
volvement is more common in these patients than is pulmonary disease. A great deal
of our understanding of this disease comes from studies of the renal pathology. In
the past few years, however, a more active search for immunologic abnormalities in
this disease has provided us with a greater understanding of the immunopathology
of the lung lesions.
Immune-complex-mediated disease is caused by the formation of antigen-
antibody complexes which fix complement and produce inflammatory injury
[15,48]. Several human diseases have been attributed to injurious effects mediated
by these complexes. Specifically, complexes activate both cellular and humoral im-
mune responses which participate in tissue injury.
Immune complexes are formed when antigen and antibody combine. As described
in the section on Goodpasture's syndrome,
the antigen can be tissue-fixed (type II
reaction, Table 1). As might be expected, injury induced by immune complexes
formed with tissue-fixed antigen is generally confined to the anatomic location of
the fixed antigen. In contrast, antigen can also be non-tissue-fixed, i.e., freely cir-
culating. In this case (type III reaction, Table 1), immune complexes induce injury in
any organ which traps these complexes. However, it should be mentioned that recent
observations challenge
the widely held theory that passive entrapment of circulating
immune complexes by
the kidney is responsible for the glomerulonephritis in SLE
and other diseases [49]. The alternative hypothesis proposed by Couser [49] suggests
that freely circulating antigen is trapped in glomeruli where antibody then reacts
with antigen to form immune complexes which induce glomerulonephritis. This
mechanism differs from the anti-tissue fixed disease, Goodpasture's syndrome, in
that the antigen, while being tissue-fixed, is not renal tissue itself. Which of these
two mechanisms predominates in causing tissue injury remains to be determined.
Of particular importance in the immunopathogenesis of disease due to circulating
immune complexes is the size of the immune complex [15,18]. Large complexes,
which form when either antigen or antibody are present in extreme excess,
do not
cause disease, as the former remain in the circulation and the latter precipitate and
are quickly cleared by the reticuloendothelial system [188. Very small complexes re-
mian soluble and probably fix complement in insufficient quantities to initiate
pathogenic mechanisms [18].
Complexes of intermediate size form in moderate an-
tigen excess, and trigger the cascade of events which culminate in tissue injury
[15,18].
These complexes small enough remain soluble
,
yet large enough to ac-
tivate the complement system and to be trapped in vessel walls.
The amount and af-
finity of antibody produced in response to antigen challenge is clearly important.
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Variability between individuals in this response may be determined genetically in
part and may account for part ofthe reason some individuals develop immune com-
plex disease and others do not [18].
Once immune complexes ofthe appropriate size are formed, a cascade ofevents is
initiated which leads to tissue injury and clinical disease (Fig. 3). The precise
chronological order of these events remains to be proven. While it is most likely
many events occur simultaneously, experimental animal data suggest that an in-
crease in the permeability of blood vessels is an early event [15,18]. The changes in
permeability appear to be mediated by vasoactive amines released when immune
complexes interact with basophils or platelets [15,18]. Activation ofthe complement
system by these complexes results in neutrophil chemotaxis to the sites of complex
deposition. Here the neutrophils release lysosomal enzymes; such as neutral pro-
teases, elastase, and collagenase, and other mediators of inflammation, such as pros-
taglandins [5,50]. The importance of neutrophils in immune-complex-mediated
tissue injury is underscored by the observation that neutrophil- and complement-
depleted animals do not develop arteritis [17]. The end result ofthese events is an in-
tense inflammatory reaction located in the arterial walls of multiple organs.
It should be emphasized that both heterologous and autologous antigens may
possibly be involved. Much ofthe experimental data discussed above is derived from
experiments using heterologous antigen. Autologous tissue may become antigenic if
I) Circulating soluble immune 2) Increased vascular permeability 3) Trapping of immune complexes
complexes in antigen excess via platelet derived vasoactive along basement membrane of
amines and Ige mediated vessel wall and activation of
reactions. complement components.
4) Complement derived chemo- 5) PMNs release lysosomal 6) Damage and necrosis of
tactic factors (C3a, C5a, enzymes (collagenase, vessel wall, thrombosis,
C567) cause accumulation elastase) occlusion, hemorrhage.
of PMNs.
FIG. 3. Circulating immune complexes of intermediate size form. Vascular
permeability is altered by vasoactive amines released from platelets or basophils
which interact with these immune complexes. The complexes are trapped in vessel
walls and activate complement which causes polymorphonuclear chemotaxis and ac-
cumulation at the site ofinjury. PMN cells release lysosomal enzymes and mediators
of inflammation which ultimately result in an intense inflammatory reaction in af-
fected vessels. (Reproduced from Fauci et al. [108] with permission of the
publisher.)
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altered by either infectious or toxic agents. Tissue perceived as "non-self" elicits the
production of antibody that complexes with it [17].
Although the most common cause ofpulmonary infiltrates in patients with SLE is
infection [51], many patients develop infiltrates without an apparent infectious
etiology [3,51-69]. Pulmonary function abnormalities can be detected in a majority
of patients without clinical or radiographic evidence of lung disease [70].
The evidence for involvement of immune complex mechanisms in the non-
infectious pulmonary manifestations of SLE is persuasive. First, both im-
munoglobulin and complement have been found in the lungs of some patients with
SLE [71-75]. Second, the pathogenic appearance of these findings suggest the le-
sions are analogous to those seen in the glomeruli [46]. Third, interstitial lung
disease has been elicited in animals following the production of circulating immune
complexes [76]. Fourth, in two recently reported patients with lupus pneumonitis
immune complexes composed of DNA, anti-DNA antibody, and complement have
been found in the interstitium of alveolar walls and alveolar capillary walls [77].
Fifth, cellular analysis of material obtained from the lungs of patients by bron-
choalveolar lavage reveals that an increased number ofneutrophils are present [78].
Sixth, immune complexes have been detected in alveolar macrophages in some pa-
tients with the lung disease associated with connective tissue disorders [79]. Alveolar
macrophages can be stimulated by immune complexes to release chemotactic factors
that attract neutrophils to the lung [80-83]. This latter finding is consistent with the
hypothesis that chemotactic factors recruit these cells to the lung where they par-
ticipate in lung injury. In this manner, the alveolar macrophage might be intimately
involved in the inflammatory reaction.
PROGRESSIVE SYSTEMIC SCLEROSIS (SCLERODERMA)
Progressive systemic sclerosis (PSS) is a disease of unknown etiology which is
characterized by widespread vascular lesions and major alterations in connective
tissue [1,79]. Because of these characteristic changes, PSS is included under the
heading of connective tissue (collagen vascular) diseases. However, unlike SLE, the
evidence is much less convincing that immune complexes have an important
pathogenic role in PSS.
The reported frequency of lung involvement in this disease varies to some extent
with the method of detection. However, either clinical or chest radiographic abnor-
malities appear in most patients sometime during the course of their disease and
some degree ofpulmonary interstitial fibrosis is almost always found at postmortem
examination [79,84-95]. Pulmonary vascular resistance is elevated in many patients
[96], but only one-half of these patients demonstrate clinical or chest radiographic
signs of right ventricular hypertrophy. It is of considerable interest that there ap-
pears to be little correlation between the degree ofpulmonary fibrosis and the sever-
ity of the pulmonary vascular lesions [79,96].
Evidence suggesting a role for immune complexes in PSS is less persuasive than
for SLE. Salerni [86] detected only small amounts of immunoglobulin G and com-
plement Ciq component in the pulmonary arteries of three patients. Small deposits
have also been described in the interlobular arteries of the kidney in PSS [97-99].
About 50 percent of patients do have hypergammaglobulinemia and approximately
50 to 60 percent demonstrate antinuclear antibodies [100]. While the response to
corticosteroids is dramatic in SLE, however, therapy with corticosteroids has not
proven effective in PSS [101,102].
18PULMONARY RENAL SYNDROMES
Additionally, pathologic examination of involved arteries reveals the predomi-
nant lesion to be intimal proliferation and/or thickening, with fibrosis and narrow-
ing ofthe vascular lumen. An arteritis is seen only occasionally in acute forms ofthe
disease [103]. It currently appears more likely, as some postulate, that a failure of
vasoregulatory mechanisms may be the initiating event and that the autoimmune
findings in PSS are epiphenomena [104].
While evidence presently is scanty for a humoral mechanism in the pathogenesis
ofthis disease, more recent studies suggest cell-mediated immunity may have an im-
portant role. Dermal cellular infiltrates in PSS consist mostly of T lymphocytes
[105]. These cells appear to be sensitized to skin extracts taken from patients with
PSS. Others have shown that normal human peripheral blood mononuclear cells,
when stimulated with phytohemaglutinin, produce a lymphokine which increases
collagen accumulation in human embryonic lung fibroblast cultures [106].
Fibroblasts isolated from patients with PSS and cultured in vitro demonstrate in-
creases in collagen accumulation over controls [107]. The fact that this effect persists
for many generations suggests that the mechanisms governing growth reside within
the cell, but does not rule out an important role for cell-mediated immunity. Lastly,
some patients with PSS develop Sjogren's syndrome which is associated, in part,
with aT-cell-mediated reaction [108]. All these factors taken together are highly sug-
gestive that cell-mediated immunity is involved in PSS.
WEGENER'S GRANULOMATOSIS
This disease has a distinctive clinico-pathologic triad of necrotizing granuloma-
tous vasculitis of the upper and lower respiratory tracts, glomerulonephritis, and
variable degrees of disseminated small vessel vasculitis [1]. The etiology of this
disease is unknown and the immunologic components have not been well defined.
Several observations suggest both immune complex (type III) and cell-mediated
(type IV) mechanisms may be involved (Table 1). First, serologic testing has revealed
the presence of rheumatoid factor in many of these patients [109-112]. Antinuclear
antibody is also seen occasionally [111]. Second, and more convincing, is the obser-
vation that circulating immune complexes [111] can be found in some patients with
active disease. The failure of others to find immune complexes may be explained by
the observation that immune reactants are often undetectable in vessel walls 24 to 48
hours after their injection into animals [109,113]. Third, in some patients, renal elec-
tron microscopic and immunofluorescence findings are consistent with immune
complex disease [114]. In other cases, granular immunofluorescent deposits have
been seen [115-118]. However, others have shown that many cases lack these
hallmarks of immune-complex-mediated disease [119].
The evidence for involvement of cell-mediated immune mechanisms is equally
suggestive. Favoring a role for cell-mediated immunity is the presence of a
characteristic necrotizing granulomatous vasculitis [15]. These lesions represent a
collection of lymphocytes, histiocytes, plasma cells, and Langhans' type giant cells.
Small arteries and veins are similarly involved. Granulomas similar to those seen in
sarcoidosis are uncommon but are occasionally seen [120]. Langhans' type giant
cells are likely formed from the coalescence and fusion of macrophages [121,122].
The presence of these cells along with a granulomatous inflammatory reaction sug-
gests type IV reactivity [121,123]. Furthermore, defects in delayed hypersensitivity
reactions [124] and impaired lymphocyte-blast transformation have been demon-
strated [125]. Accordingly, the suspicion that hypersensitivity mechanisms may be
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involved [121,126] persists [123]. As suggested by Fauci et al. [109], it is possible that
circulating antigen triggers sensitized lymphocytes to release lymphokines which in-
itiate a granulomatous reaction with granuloma and giant cell formation (Fig. 4).
Alternatively, immune complexes may be phagocytosed by macrophages, resulting
in activation of this cell and initiating granuloma formation [109] (Fig. 4).
In summary, perturbations in both humoral and cell-mediated immunity appear
to be present. It remains unclear whether the immune system has primary impor-
tance in the pathogenesis of this disease.
LYMPHOMATOID GRANULOMATOSIS
Lymphomatoid granulomatosis is a disease grouped, along with Wegener's
granulomatosis, under the heading of granulomatous vasculitis [1]. While in certain
cases it is difficult to distinguish this entity from Wegener's granulomatosis, impor-
tant pathological differences exist which suggest different immunopathological
mechanisms may be operating. First, the characteristic pathology of this disease is
an angiotrophic and angiodestructive infiltration of tissues by atypical lym-
phomatoid and plasmacytoid cells [127]. Second, in this disease the "granulomato-
sis" consists of necrotic foci, occasionally involving areas infiltrated with these
atypical cells, but also occasionally involving lung tissue not extensively infiltrated
and in continuity with necrotic vessels [127]. Third, small noncaseating sarcoid-like
granulomas were found in only one ofthe first 40 cases reported [127]. Fourth, Lang-
hans' type giant cells are also conspicuously absent [127-129]. Fifth, these findings
are in contrast to the pathologic findings in Wegener's granulomatosis [112] pre-
viously described. Sixth, the renal disease is not a glomerulonephritis as seen in
Sensitized Lymphocyte Mocrophage
, ~ Complexes
Lymphokines
Antigen
Complement + PMNs
Activoted Macrophage
\4SOnI Enzymes
0^X0 ~~~~~~~~~~Vasculitis
Granuloma
FIG. 4. Immune complex and cell-mediated immune mechanisms of
granulomatous vasculitis. (Adapted from Fauci et al. [108] with per-
mission ofthepublisher.) Antigen interacts with lymphocytes, causing
the release of lymphokines which recruit and activate macrophages.
The activated macrophage may also result from interaction with im-
mune complexes. Activated macrophages may ultimately evolve into
granulomas. In addition, this cell complement and polymorphonuclear
cells (PMN) induce a vascular inflammatory reaction.
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Wegener's [112]. Seventh, Liebow et al., in their original description of this entity,
stressed that there is no clear evidence of an autoimmune state [127]. Eighth, an-
tinuclear antibodies have been reported as negative [112,127,130], and only rarely
has a patient had a positive rheumatoid factor [127].
Others have speculated that an acquired abnormality of the lymphocyte may be
involved, based on the absence of delayed hypersensitivity to skin test antigens, in-
cluding dinitrochloro-benzene, and the response of the lung lesions to cor-
ticosteroids [130]. Liebow et al. [127] were impressed by the lack of obvious
evidence of autoimmune phenomena and suggested that a viral agent may be the
cause.
In summary, adequate numbers of cases have not been studied with the aim of
delineating immunologic perturbations to permit a conclusion about a potential
pathogenetic role for the immune system in this disease. Clearly, this is a fruitful
area for future investigations.
ALLERGIC ANGIITIS AND GRANULOMATOSIS
(CHURG-STRAUSS SYNDROME)
Churg and Strauss first described this syndrome in 1951 [131]. It is a disease which
in some ways strongly resembles classic polyarteritis nodosa (PAN) but also has
several distinguishing features: association with an allergic diathesis, prominent lung
involvement manifested by eosinophilic infiltrates, and the presence of vascular and
extravascular granulomas [15,131-133]. Complete data on the immunological aber-
rancies in this disease are lacking. The rarity ofthe disease contributes to our limited
insight into its immunopathogenesis.
Much of the evidence supporting a role for immune mechanisms in this disease
has been extrapolated from the apparently closely related disease, PAN. An associa-
tion, in some cases, between the classic form ofPAN and hepatitis B antigenemia is
now well established [112,134]. Moreover, additional studies suggest that immune
complexes of hepatitis B antigen and antibody may be playing an important role in
the pathogenesis of PAN [1351. Because Churg-Strauss syndrome possesses some of
the pathologic abnormalities seen in PAN, it is reasonable to speculate that similar
immunologic mechanisms of tissue injury may be involved. First, several patients
have been found to possess positive rheumatoid factor [133]. Most of these titers
were low, but two patients had titers > 1:2,560. Second, one patient has been
described with immunofluorescent evidence for immunoglobulin and complement in
the pulmonary vascular lesions [136].
The fact that this disease occurs primarily in patients with an allergic background
or asthma or both may also be etiologically significant [131]. The presence of
eosinophilia and serum elevations of IgE [133] in some of these patients suggests
that an immediate hypersensitivity (type I) reaction may be involved [15] (Table 1).
In this regard, it is of interest that in one series asthma was present for a mean of
eight years prior to the detection ofvasculitis [133]. It remains unclear whether these
findings are an early manifestation of the disease or somehow predispose to its
development.
The characteristic pathologic changes in this syndrome include necrotizing ex-
travascular granulomas and necrotizing vasculitis of small arteries and veins
[131,133]. Giant cells of the Langhans' type are also present frequently [131].
Similar giant cells are seen in some cases ofWegener's granulomatosis, as previously
discussed, and they suggest that cell-mediated immune mechanisms also may be in-
volved [121,123].
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In summary, it must be emphasized that the above observations really are only
tantalizing clues to the immunologic mechanisms that may be involved. The current
sophistication of our ability to survey many components ofthe immune system will,
we hope, soon be used to improve our understanding of the pathogenesis of this
disease.
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